Bausch Health Cos Inc. $BHC Shares Sold by Gamco Investors INC. ET AL

Gamco Investors INC. ET AL lessened its holdings in shares of Bausch Health Cos Inc. (NYSE:BHC) by 14.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 748,743 shares of the company’s stock after selling 125,709 shares during the period. Gamco Investors INC. ET AL’s holdings in Bausch Health Cos were worth $4,043,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of BHC. Public Employees Retirement System of Ohio lifted its stake in Bausch Health Cos by 112.8% in the 1st quarter. Public Employees Retirement System of Ohio now owns 429,208 shares of the company’s stock worth $2,312,000 after purchasing an additional 227,466 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of Bausch Health Cos by 10.8% in the first quarter. Dimensional Fund Advisors LP now owns 3,604,818 shares of the company’s stock valued at $19,456,000 after purchasing an additional 350,823 shares in the last quarter. Bessemer Group Inc. grew its position in shares of Bausch Health Cos by 146.3% in the first quarter. Bessemer Group Inc. now owns 33,257 shares of the company’s stock valued at $180,000 after purchasing an additional 19,757 shares in the last quarter. J. Safra Sarasin Holding AG acquired a new position in Bausch Health Cos during the first quarter worth $190,000. Finally, Range Financial Group LLC boosted its stake in Bausch Health Cos by 10.2% during the first quarter. Range Financial Group LLC now owns 193,925 shares of the company’s stock worth $1,047,000 after buying an additional 17,929 shares during the last quarter. Institutional investors and hedge funds own 78.65% of the company’s stock.

Insider Transactions at Bausch Health Cos

In related news, Director Frank D. Lee sold 24,456 shares of the business’s stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $5.43, for a total value of $132,796.08. Following the sale, the director directly owned 49,339 shares in the company, valued at approximately $267,910.77. The trade was a 33.14% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 20.67% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on BHC. Weiss Ratings cut Bausch Health Cos from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, May 4th. Jefferies Financial Group raised shares of Bausch Health Cos to a “hold” rating in a research report on Wednesday, July 22nd. Finally, Royal Bank Of Canada dropped their price objective on shares of Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating for the company in a report on Monday, April 27th. Five research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Bausch Health Cos currently has a consensus rating of “Reduce” and an average target price of $8.00.

Bausch Health Cos Price Performance

BHC stock opened at $4.49 on Tuesday. The business has a fifty day moving average of $4.98 and a two-hundred day moving average of $5.52. The company has a quick ratio of 0.97, a current ratio of 1.32 and a debt-to-equity ratio of 54.68. The stock has a market cap of $1.68 billion, a price-to-earnings ratio of -1.38 and a beta of 0.42. Bausch Health Cos Inc. has a 52-week low of $4.33 and a 52-week high of $8.69.

Bausch Health Cos (NYSE:BHC) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $0.78 EPS for the quarter, missing the consensus estimate of $0.81 by ($0.03). Bausch Health Cos had a negative net margin of 11.47% and a negative return on equity of 2,922.77%. The business had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.37 billion. As a group, research analysts anticipate that Bausch Health Cos Inc. will post 4.05 earnings per share for the current year.

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.